Announced Mon, 6 Jul · 19:04 IST
Sun Pharma 34th AGM on 31 July 2026; FY26 revenue up 11.9% to Rs 582B
Board & Shareholder Meetings View source PDF
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-1.4%1-day move
₹1913.60
prior close
₹1900.60
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.5+0.4+0.6+0.8-1.4+1.4+1.0+0.4+1.6+2.0————
Up moveDown movePending
AI summary
Sun Pharma has filed Notice of 34th AGM on 31 July 2026 via video conferencing, with FY26 Annual Report. E-voting runs 27-30 July. FY26 results: revenue up 11.9% to Rs 582B, EBITDA up 16.1% to Rs 177B, net profit up 5% to Rs 115B. India formulation sales rose 14% to Rs 193B. Innovative Medicines now 22% of sales, surpassing US generics share. Leadership transition: Kirti Ganorkar became MD. Organon acquisition announced.
Likely market impact
Shareholders can review the Annual Report and vote during e-voting window 27-30 July. FY26 growth and Organon acquisition signal continued momentum.